+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Addiction Disorders Drugs Market by Indication, Product Type, Route Of Administration, Dosage Form, Distribution Channel, End User - Global Forecast to 2030- Product Image
Addiction Disorders Drugs Market by Indication, Product Type, Route Of Administration, Dosage Form, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Addiction Disorders Drugs Market by Indication, Product Type, Route Of Administration, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5337785
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Addiction Disorders Drugs Market grew from USD 27.08 billion in 2024 to USD 28.89 billion in 2025. It is expected to continue growing at a CAGR of 6.48%, reaching USD 39.49 billion by 2030.

Addressing the Evolving Challenges of Addiction Disorders

As global healthcare systems confront a surge in substance use disorders, the demand for effective pharmacological interventions has never been more pressing. The burden of addiction transcends socioeconomic boundaries, placing immense strain on patients, caregivers, and providers alike. This executive summary distills the essential findings and strategic implications from an in-depth examination of the addiction disorders drug market, offering stakeholders a concise yet comprehensive overview of prevailing dynamics.

By synthesizing data across therapeutic classes, regulatory shifts, and evolving stakeholder priorities, our analysis illuminates the key drivers shaping treatment paradigms. Throughout this document, you will discover how novel clinical approaches, policy reforms, and market forces are converging to redefine patient care models. Whether you represent a pharmaceutical innovator, a healthcare provider, or an investment analyst, the insights presented here will inform your strategic decision making and position you to capitalize on emerging opportunities.

Pivotal Transformations Reshaping the Addiction Disorder Therapeutics Landscape

Over the past decade, the addiction therapeutics landscape has undergone profound transformation, propelled by breakthroughs in neuroscience and a heightened emphasis on personalized medicine. Digital therapeutics and telehealth solutions have augmented traditional pharmacotherapy, facilitating patient adherence and extending the reach of evidence-based care. Concurrently, the approval of novel opioid antagonists and long-acting formulations has redefined maintenance strategies, enabling clinicians to tailor regimens with greater precision.

Amid these advancements, societal attitudes toward addiction are shifting, reducing stigma and encouraging earlier intervention. Collaborations between payers and providers are driving value-based payment models, incentivizing outcomes rather than volume. Moreover, regulatory agencies are streamlining approval pathways for therapies targeting high-unmet-need indications, accelerating time to market. These transformative shifts underscore a broader trend toward integrated, patient-centric frameworks that prioritize holistic recovery over symptom suppression.

Assessing the Ripple Effects of 2025 US Tariff Policies on Drug Supply Chains

In 2025, the introduction of new United States tariffs on active pharmaceutical ingredients and drug imports has generated ripple effects across the supply chain. Manufacturers dependent on overseas raw materials have confronted increased production costs, prompting adjustments in pricing strategies and contract negotiations. These cost pressures have been most pronounced for generics and off-patent formulations, where margins are inherently constrained.

To mitigate the impact, several stakeholders have diversified supplier networks, exploring domestic sourcing and vertical integration initiatives. Some companies have accelerated innovation pipelines to offset higher input costs through premium product launches. Meanwhile, payers and providers are recalibrating formularies to balance budgetary constraints with clinical efficacy, favoring therapies that demonstrate robust real-world outcomes. As the market adapts to this new tariff environment, agility and supply chain resilience have emerged as critical differentiators for industry participants.

Unveiling Granular Market Segments Driving Therapeutic Adoption

When examining the market by therapeutic indication, four principal categories emerge: alcohol dependence, opioid dependence, smoking cessation, and stimulant dependence. The alcohol dependence segment delves into the utilization patterns of acamprosate, disulfiram and naltrexone, highlighting shifts toward extended-release formulations that improve adherence. In opioid dependence, buprenorphine, methadone and naltrexone each present unique safety and efficacy profiles, with recent formulations emphasizing reduced diversion risk. Smoking cessation therapies encompass bupropion and varenicline alongside nicotine replacement options such as gum, inhaler, lozenge and patch, reflecting a trend toward combination approaches that leverage both behavioral and pharmacological mechanisms. Off-label and investigational compounds dominate the stimulant dependence space, underscoring an area ripe for clinical innovation.

Delineating by product type reveals a dynamic interplay between branded franchises and generic alternatives, with competition driving cost optimization and access expansion. Analysis of routes of administration uncovers a growing preference for oral therapies, tempered by targeted growth in injectable intramuscular and intravenous formats, as well as sublingual films and tablets. Transdermal patches continue to gain traction for their steady-state delivery capabilities. Across dosage forms, capsules, tablets and injectable solutions remain foundational, yet novel film-based formulations are carving out new niches. Distribution channels vary from hospital pharmacies to online platforms and retail outlets, each adapting to shifting patient demands. End-user environments span clinics, homecare settings and hospitals, reflecting the multi-modal nature of addiction treatment pathways.

Decoding Regional Dynamics Across the Americas, EMEA, and Asia-Pacific

Regional analysis reveals distinct market dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, high healthcare expenditure coupled with well-established regulatory frameworks fosters rapid uptake of innovative therapies, particularly in opioid and alcohol dependence. The convergence of public and private payer systems has also facilitated broad access initiatives, driving prescription volume growth.

Within Europe, Middle East and Africa, heterogeneity in healthcare infrastructure and reimbursement policies yields varied adoption rates. Western European markets emphasize evidence-based formulary inclusion and tend to favor branded medications, whereas emerging economies in the Middle East and Africa show heightened demand for cost-effective generic solutions. Collaborative agreements between local authorities and multinational corporations are instrumental in expanding treatment accessibility.

The Asia-Pacific region is characterized by escalating investment in mental health programs and an accelerating shift toward outpatient care models. Nations such as Japan and Australia are pioneering long-acting injectable therapies, while Southeast Asian countries prioritize scalable, low-cost interventions. Regulatory reforms aimed at streamlining clinical trial processes are attracting significant R&D interest, positioning the region as a key growth frontier.

Profiling Leading Stakeholders Steering Innovation and Market Growth

Key players are deploying multifaceted strategies to consolidate their market positions and advance therapeutic frontiers. Leading pharmaceutical companies have fortified their pipelines through acquisitions of biotech innovators specializing in novel receptor targets and long-acting delivery platforms. Strategic alliances are enabling the co-development of combination therapies that integrate pharmacological agents with digital adherence solutions.

Generic manufacturers are leveraging scale efficiencies to penetrate value-driven markets, while niche biotech firms concentrate on underserved indications and precision medicine approaches. Contract research organizations and specialty pharmacies have also emerged as vital partners, delivering integrated services that streamline patient onboarding and support adherence monitoring. The competitive landscape continues to evolve as emerging entrants pursue orphan drug designations and expedited approval pathways, challenging incumbents to maintain agility and clinical leadership.

Strategic Pathways for Industry Leaders to Navigate Future Challenges

Industry leaders should prioritize portfolio diversification by balancing established therapies with novel modalities that address unmet needs. Investment in real-world evidence generation will strengthen payer negotiations and support value-based contracting. Cultivating partnerships with digital health providers can amplify patient engagement and adherence metrics, enhancing clinical and economic outcomes.

Supply chain resilience must be reinforced through dual sourcing strategies and advanced inventory management systems to mitigate tariff and geopolitical risks. Organizations are advised to explore regional manufacturing hubs to reduce import dependencies and shorten lead times. Engaging with regulatory bodies to shape policy frameworks will facilitate faster approval pathways and market access for innovative treatments.

Finally, adopting patient-centric service models that integrate pharmacotherapy with psychosocial support will differentiate offerings in a crowded marketplace. Embedding predictive analytics into care delivery can anticipate relapse risks and tailor interventions, ensuring sustained patient recovery and long-term market growth.

Rigorous Multimodal Approach Underpinning the Market Analysis

This analysis is grounded in a multimodal research framework that integrates primary interviews with key opinion leaders, clinical trial registries, and regulatory filings. Secondary data sources include peer-reviewed journals, industry white papers, and proprietary databases that track prescription volumes and pricing trends. Quantitative insights were validated through cross-referencing real-world utilization data, while qualitative perspectives were gleaned from stakeholder workshops and advisory panels.

Segmentation modeling employed a top-down approach, mapping therapeutic classes against treatment pathways, administration routes and end-user settings. Regional market assessments combined macroeconomic indicators with healthcare infrastructure metrics to derive comparative insights. Competitive intelligence was synthesized from patent landscapes, partnership announcements and financial disclosures. Rigorous data triangulation and iterative validation rounds underpin the robustness of the findings, ensuring both accuracy and relevance for strategic decision making.

Synthesizing Insights to Empower Informed Decision Making

The landscape of addiction disorder therapeutics is poised at an inflection point, where clinical innovation intersects with shifting policy environments and market forces. Stakeholders equipped with granular segmentation insights, regional nuance and competitive intelligence can anticipate emerging trends and craft winning strategies. Resilience in supply chain management, coupled with a steadfast focus on patient-centric care, will define the next era of market leadership.

By leveraging the comprehensive analysis presented in this summary, decision makers can navigate complexities with confidence, drive sustainable growth and ultimately improve patient outcomes. The convergence of advanced therapeutics, integrated care models and outcome-based contracting heralds a transformative period in addiction treatment, offering both challenges and opportunities for visionary organizations.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Alcohol Dependence
      • Acamprosate
      • Disulfiram
      • Naltrexone
    • Opioid Dependence
      • Buprenorphine
      • Methadone
      • Naltrexone
    • Smoking Cessation
      • Bupropion
      • Nicotine Replacement Therapy
        • Gum
        • Inhaler
        • Lozenge
        • Patch
      • Varenicline
    • Stimulant Dependence
      • Off Label Drugs
      • Research Drugs
  • Product Type
    • Branded
    • Generic
  • Route Of Administration
    • Injectable
      • Intramuscular
      • Intravenous
    • Oral
    • Sublingual
      • Film
      • Tablet
    • Transdermal
      • Patch
  • Dosage Form
    • Capsule
    • Film
    • Injectable Solution
    • Patch
    • Tablet
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Homecare Settings
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Johnson & Johnson
  • Indivior plc
  • Alkermes plc
  • Camurus AB
  • Orexo AB
  • BioDelivery Sciences International, Inc.
  • Titan Pharmaceuticals, Inc.
  • Mallinckrodt plc
  • Teva Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Addiction Disorders Drugs Market, by Indication
8.1. Introduction
8.2. Alcohol Dependence
8.2.1. Acamprosate
8.2.2. Disulfiram
8.2.3. Naltrexone
8.3. Opioid Dependence
8.3.1. Buprenorphine
8.3.2. Methadone
8.3.3. Naltrexone
8.4. Smoking Cessation
8.4.1. Bupropion
8.4.2. Nicotine Replacement Therapy
8.4.2.1. Gum
8.4.2.2. Inhaler
8.4.2.3. Lozenge
8.4.2.4. Patch
8.4.3. Varenicline
8.5. Stimulant Dependence
8.5.1. Off Label Drugs
8.5.2. Research Drugs
9. Addiction Disorders Drugs Market, by Product Type
9.1. Introduction
9.2. Branded
9.3. Generic
10. Addiction Disorders Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intramuscular
10.2.2. Intravenous
10.3. Oral
10.4. Sublingual
10.4.1. Film
10.4.2. Tablet
10.5. Transdermal
10.5.1. Patch
11. Addiction Disorders Drugs Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.3. Film
11.4. Injectable Solution
11.5. Patch
11.6. Tablet
12. Addiction Disorders Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Addiction Disorders Drugs Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Homecare Settings
13.4. Hospitals
14. Americas Addiction Disorders Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Addiction Disorders Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Addiction Disorders Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Johnson & Johnson
17.3.3. Indivior plc
17.3.4. Alkermes plc
17.3.5. Camurus AB
17.3.6. Orexo AB
17.3.7. BioDelivery Sciences International, Inc.
17.3.8. Titan Pharmaceuticals, Inc.
17.3.9. Mallinckrodt plc
17.3.10. Teva Pharmaceutical Industries Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ADDICTION DISORDERS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ADDICTION DISORDERS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ADDICTION DISORDERS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ADDICTION DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ADDICTION DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ADDICTION DISORDERS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ACAMPROSATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISULFIRAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY METHADONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BUPROPION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY LOZENGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY VARENICLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OFF LABEL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY RESEARCH DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY FILM, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY FILM, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 91. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 93. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 94. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 95. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 96. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 97. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 98. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 100. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 101. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 102. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 103. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 107. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 110. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 114. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 115. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 116. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 117. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 179. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 180. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 181. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 182. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 185. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 186. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 187. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 188. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 192. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 193. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 194. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 195. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 196. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 199. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 200. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 201. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 202. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 220. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 221. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 222. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 223. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 224. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 225. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 227. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 228. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 229. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 230. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 234. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 235. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 236. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 237. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 238. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 241. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 242. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 243. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 244. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 289. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 290. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 291. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 292. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 293. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 294. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 297. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 298. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 299. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 300. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. DENMARK ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 303. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 304. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 305. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY SMOKING CESSATION, 2018-2030 (USD MILLION)
TABLE 306. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 307. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY STIMULANT DEPENDENCE, 2018-2030 (USD MILLION)
TABLE 308. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 309. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 311. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 312. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 313. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-

Companies Mentioned

The companies profiled in this Addiction Disorders Drugs market report include:
  • Pfizer Inc.
  • Johnson & Johnson
  • Indivior plc
  • Alkermes plc
  • Camurus AB
  • Orexo AB
  • BioDelivery Sciences International, Inc.
  • Titan Pharmaceuticals, Inc.
  • Mallinckrodt plc
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 28.89 Billion
Forecasted Market Value ( USD ) by 2030 $ 39.49 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Addiction Treatment - Global Strategic Business Report - Product Image

Addiction Treatment - Global Strategic Business Report

  • Report
  • 242 Pages
  • Global
From
Addictions Therapeutics Market Report 2025 - Product Image

Addictions Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Substance Abuse and Addiction Treatment Market Report 2025 - Product Image

Substance Abuse and Addiction Treatment Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Smoking Cessation & Nicotine De-Addiction Product Market by Product Type, Route Of Administration, Distribution Channel, End User, Nicotine Strength, Age Group - Global Forecast to 2030 - Product Image

Smoking Cessation & Nicotine De-Addiction Product Market by Product Type, Route Of Administration, Distribution Channel, End User, Nicotine Strength, Age Group - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Smoking Cessation And Nicotine De-addiction Market Size, Share & Trends Analysis Report By Type (Nicotine Replacement Therapy), By Form, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Smoking Cessation And Nicotine De-addiction Market Size, Share & Trends Analysis Report By Type (Nicotine Replacement Therapy), By Form, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.